GI Innovation, Inc.
Clinical trials sponsored by GI Innovation, Inc., explained in plain language.
A biotech company developing immunotherapies and cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug GI-108 enters human trials for advanced tumors Results expected Feb 2027 (estimated)
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a drug and probiotic combo turn back the clock on aging?
Disease control Recruiting nowThis early-phase trial is testing whether a combination of a drug (GI-102) and a probiotic supplement (GIB-7) can improve markers of aging in the immune system. The study includes 15 healthy adults and cancer survivors aged 18 to 80. Participants will receive either the active co…
Phase 2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New cancer drug GI-108 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:00 UTC